TraceLink Drives Pharma Industry Transformation, Reports 2014 Annual Revenue Growth of 137% and Two-Year Revenue CAGR of 91%
January 1 2015 US Drug Supply Chain Security Act Deadline Accelerates Adoption of Company's Life Sciences Cloud Platform by Pharmaceutical Manufacturers and Distributors
(firmenpresse) - WAKEFIELD, MA -- (Marketwired) -- 02/02/15 -- ., the leader in protecting patient safety and enabling health for global Life Sciences, today announced record fourth quarter and full-year growth for 2014. As US pharmaceutical manufacturers and distributors worked to meet track and trace compliance requirements under the (DSCSA), which became law on January 1, 2015, TraceLink experienced widespread customer adoption of its platform. The company achieved a 173% increase in new customers for Q4, and a 680% increase in new customers year-over-year (YoY). These new customers wins, which range from large global pharmaceutical conglomerates to smaller wholesale distributors and pharmacy chains, contributed to a YoY revenue increase of 137% -- and a two-year revenue compound annual growth rate (CAGR) of 91%.
"The past year has been a defining moment for our industry, our customers, and our company. We're very pleased with our results, and we see even larger opportunities in front of us," said Shabbir Dahod, president and CEO of TraceLink. "In the US, DSCSA has many phases and pharmaceutical suppliers are already working to address the complex requirements of serializing their products in advance of the 2017 deadlines. At the same time, new and emerging regulations are fast approaching across a broad range of countries in Latin America, Asia and Europe. Our differentiated network platform, proven success with customers, and continued financial momentum put TraceLink in an excellent position to capitalize on these converging opportunities and drive steady increases to our global market share."
Other significant TraceLink growth milestones for 2014 included:
-- the first and largest track and trace network for the pharmaceutical industry that enables manufacturers, distributors and dispensers to create and share required compliance documents with their trading partners;
-- with 15 of the top-20 global pharma companies now using TraceLink solutions;
-- all with DSCSA compliant Advance Shipping Notices (ASNs);
-- further reinforcing TraceLink's overall market share leadership of track and trace solutions for the Life Sciences industry;
-- to accommodate increasing customer demand, both domestically and internationally; and,
-- including the November 2014 delivery of the preferred document specifications established by each member of the Big Three wholesale distributors, AmerisourceBergen, Cardinal Health, and McKesson.
To learn more about meeting global pharmaceutical compliance deadlines designed to combat drug counterfeiting, and how to build a flexible global serialization, track and trace, and reporting platform for Brazil, China and other countries, visit .
TraceLink protects patients, enables health and ensures compliance for companies across the global Life Sciences supply network, including fifteen of the top-20 global pharmaceutical companies. Leading businesses trust the TraceLink Life Sciences Cloud, our Amazon AWS-based cloud application platform, to deliver complete global connectivity, visibility and traceability of pharmaceuticals from ingredient to patient. A single point and click connection to the Life Sciences Cloud creates a supply chain control tower that delivers the information, insight and collaboration needed to improve performance and reduce risk across global supply, manufacturing and distribution operations. Winner of numerous industry awards including the Amazon AWS Global Start-Up Challenge Grand Prize and the Edison Award for Innovation in Health Management, the TraceLink Life Sciences Cloud is used by businesses across the globe to meet strategic goals in ensuring global compliance, fighting drug counterfeiting, improving on-time and in-full delivery, protecting product quality and reducing operational cost. For more information on TraceLink and our solutions, visit or follow us on .
TraceLink is funded by FirstMark Capital. FirstMark Capital is an early stage venture capital firm based in New York City. FirstMark's mission is to partner with exceptional entrepreneurs who are changing the world by solving meaningful problems. FirstMark has built a deeply engaged community among the extraordinary teams in the FirstMark network to spread ideas and opportunities. FirstMark is privileged to work alongside the founders of remarkable businesses like Pinterest, Lumosity, TapAd, Shopify, Riot Games, and dozens more. Visit FirstMark in New York City or online at and .
Laura MacSweeney
Red Javelin Communications
(781) 395-6420
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.02.2015 - 13:30 Uhr
Sprache: Deutsch
News-ID 368417
Anzahl Zeichen: 0
contact information:
Town:
WAKEFIELD, MA
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 220 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TraceLink Drives Pharma Industry Transformation, Reports 2014 Annual Revenue Growth of 137% and Two-Year Revenue CAGR of 91%"
steht unter der journalistisch-redaktionellen Verantwortung von
TraceLink (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
